Details of the Drug
General Information of Drug (ID: DM7TM91)
| Drug Name |
ELAROFIBAN
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Elarofiban; RWJ-53308; UNII-T9YH5NSL8U; T9YH5NSL8U; 198958-88-2; CHEMBL87728; (3s)-3-[({(3r)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]-3-(pyridin-3-yl)propanoic acid; Elarofiban [INN]; AC1L50BO; AC1Q5T2G; SCHEMBL1650115; CTK4E2665; BDBM50104600; AKOS027326865; (S)-beta-((R)-1-(3-(4-Piperidyl)propionyl)nipecotamido)-3-pyridinepropionic acid; (S)-3-{[(R)-1-(3-Piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-3-pyridin-3-yl-propionic acid
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 416.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -2.2 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Thrombosis | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | DB61-GB90 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References


